查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1771704

呼吸道融合细胞病毒疫苗市场规模、份额、趋势分析报告：按类型、技术、目标人口、分销管道、地区、细分市场、预测至 2025-2030 年

Respiratory Syncytial Virus Vaccines Market Size, Share & Trends Analysis Report By Type (Passive Immunization, Preventive Vaccines), By Technology, By Targeted Population, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

呼吸道融合细胞病毒(RSV) 疫苗市场成长与趋势：

根据 Grand View Research, Inc. 的最新报告，全球呼吸道融合细胞病毒疫苗市场规模预计到 2030 年将达到 283.9 亿美元，2025 年至 2030 年的复合年增长率为 42.17%。随着人口老化和 COPD、气喘和糖尿病等併发症变得越来越普遍，对疫苗接种等预防措施的需求只会增加。 RSV 疫苗在多个年龄层中的核准大大扩展了潜在市场。此外，越来越多的政府支持，包括公共疫苗宣传活动，有助于推动疫苗接种和市场渗透。 RSV 越来越被认识到是全球重大的公共卫生威胁，凸显了持续创新和投资该领域的重要性。

推动市场成长的关键因素是公共卫生当局扩大疫苗建议范围。 2025 年 4 月，美国免疫实践咨询委员会 (ACIP) 决定向 50-59 岁患有严重 RSV 疾病风险较高的成年人推荐包括葛兰素史克的 AREXVY 在内的 RSV 疫苗。这包括患有气喘、慢性阻塞性肺病(COPD)、糖尿病、心臟病等慢性疾病的人以及长期照护机构的居民。这项建议建立在 ACIP 2024 年 6 月投票的基础上，该投票建议所有 75 岁及以上的成年人以及 60-74 岁有潜在健康风险的成年人接种疫苗。此类政策扩展对于提高疫苗接种率和增加 AREXVY 等产品的商业性潜力至关重要，从而进一步刺激 RSV 疫苗市场。

技术创新和产品差异化也是塑造呼吸道合胞病毒（RSV）疫苗市场的关键力量。 mRNA 和佐剂疫苗平台的突破正在提升疫苗的有效性、安全性和给药的便利性。例如，Moderna 的 mRNA 疫苗 mRESVIA 已于 2024 年 5 月核准，适用于 60 岁及以上成年人，这是该公司第二款获得 FDA核准的mRNA 疫苗，展现了 mRNA 技术在感染疾病预防领域的强劲发展势头。葛兰素史克的 AREXVY 利用佐剂配方来增强老年人，尤其是免疫力较弱的老年人的免疫反应。针对不同族群提供多种疫苗选择将有助于促进竞争，同时扩大疫苗的可及性并增强市场对呼吸道合胞病毒疫苗有效性的信心。

公共和私营部门的投入不断增加，加速了临床试验和监管核准的步伐。辉瑞、Moderna、葛兰素史克和默克等大型製药公司正积极透过大规模3期临床试验探索新的适应症和年龄层。辉瑞继续将其呼吸道合胞病毒疫苗ABRYSVO推广至更年轻的族群。预计这些进展将长期促进竞争、改善产品创新并降低成本，这对于维持长期市场成长至关重要，尤其是在新兴经济体。

此外，与全球卫生组织伙伴关係以及分级定价策略对于扩大中低收入国家呼吸道合胞病毒疫苗的可及性至关重要。随着呼吸道合胞病毒的季节性和传播模式因气候变迁和全球流动性而发生变化，综合监测和响应迅速的疫苗接种政策将变得越来越重要。随着指南的不断完善和强大的创新管道，呼吸道合胞病毒疫苗市场有望持续成长并对公共卫生产生积极影响。

呼吸道融合细胞病毒疫苗市场报告重点

  • 2024 年，被动免疫占据主导地位，市场占有率达 75.02%，主要得益于单株抗体 (mAb) 疗法的进步。
  • 单株抗体 (mAb) 领域在 2024 年占据了主导市场占有率。 mAb 可提供即时被动免疫，因此是保护新生儿和免疫力缺乏患者等高风险族群的理想选择。
  • 由于婴儿和儿童疾病负担较重以及近期预防方面的突破，预计到 2024 年将占据最大的市场占有率，达到 75.02%。 RSV 是全球婴儿和儿童住院的主要原因，因此迫切需要有效的预防措施。
  • 受需求成长、疫苗供应增加和疫苗接种计画扩大的推动，预计到 2024 年，医院和零售药局将占据 53.68% 的市场份额。
  • 由于 RSV感染疾病率高且医疗保健基础设施先进，北美在全球 RSV 疫苗市场占有很大份额。
  • 全球RSV疫苗市场竞争激烈，阿斯特捷利康、赛诺菲、葛兰素史克、辉瑞、Moderna、Icosavax、Meissa Vaccines、Codagenix、蓝湖生物技术、默克等主要企业均专注于疫苗强化。

目录

第一章调查方法与范围

第二章执行摘要

3. RSV呼吸道融合细胞病毒市场变数、趋势和范围

  • 市场介绍/电网展望
  • 市场规模和成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 呼吸道融合细胞病毒（RSV）疫苗市场分析工具
    • 波特分析
    • PESTEL分析

第四章市场：类型评估与趋势分析

  • 细分仪表板
  • 市场：2024 年和 2030 年类型变化分析
  • 被动免疫
  • 预防性疫苗

第五章 市场：技术评估/趋势分析

  • 细分仪表板
  • 市场：2024 年和 2030 年技术变革分析
  • 单株抗体
  • 重组蛋白+佐剂
  • 基于mRNA的疫苗
  • 类病毒颗粒（VLP）

第六章 市场：目标人口估算与趋势分析

  • 细分仪表板
  • 市场：2024 年和 2030 年目标人口变化分析
  • 成人
  • 婴儿

第七章市场：通路评估及趋势分析

  • 细分仪表板
  • 市场：2024 年和 2030 年分销通路变化分析
  • 医院和药房
  • 政府供应商
  • 其他的

第 8 章市场：区域评估/趋势分析

  • 2024 年及 2030 年各地区市场占有率
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 公司热图分析
  • 公司简介
    • AstraZeneca
    • Sanofi
    • GSK
    • Pfizer Inc.
    • Moderna
    • Icosavax
    • Meissa Vaccines
    • Codagenix
    • Blue Lake Biotechnology
    • Merck &Co., Inc.
Product Code: GVR-4-68040-625-1

RSV Vaccines Market Growth & Trends:

The global respiratory syncytial virusvaccines market size is expected to reach USD 28.39 billion by 2030, registering a CAGR of 42.17% from 2025 to 2030, according to a new report by Grand View Research, Inc. As populations age and comorbidities such as COPD, asthma, and diabetes become more prevalent, the demand for preventive measures like vaccination continues to rise. Regulatory approvals of RSV vaccines across multiple age groups have significantly expanded the addressable market. Furthermore, growing government support, including public immunization campaigns, has helped boost vaccination uptake and market penetration. The increasing global recognition of RSV as a serious public health threat underlines the importance of continued innovation and investment in this sector.

A key factor propelling market growth is the expansion of vaccine recommendations by public health authorities. In April 2025, the U.S. Advisory Committee on Immunization Practices (ACIP) voted to recommend RSV vaccines, including GSK's AREXVY, for adults aged 50-59 who are at elevated risk of severe RSV disease. This includes individuals with chronic conditions such as asthma, chronic obstructive pulmonary disease (COPD), diabetes, heart disease, and those residing in long-term care facilities. This recommendation builds upon ACIP's earlier vote in June 2024 to advise vaccination for all adults aged 75 and older, and for those aged 60-74 with underlying health risks. These policy expansions are critical in driving vaccine coverage and boosting the commercial viability of products like AREXVY, further energizing the RSV vaccine market.

Technological innovation and product differentiation are also vital forces shaping the RSV vaccine landscape. Breakthroughs in mRNA and adjuvanted vaccine platforms have improved efficacy, safety profiles, and delivery convenience. For example, Moderna's mRESVIA, approved in May 2024 for adults aged 60 and older, represents the company's second FDA-approved mRNA vaccine and highlights the momentum of mRNA technologies in infectious disease prevention. GSK's AREXVY leverages an adjuvanted formulation to enhance immune response in older adults, especially those with weakened immune systems. The availability of multiple vaccine options tailored to different population segments supports competition while broadening access and boosting market confidence in RSV vaccine efficacy.

Increased investments from both public and private sectors are accelerating the pace of clinical trials and regulatory approvals. Major pharmaceutical companies such as Pfizer, Moderna, GSK, and Merck are actively pursuing new indications and age groups through extensive Phase 3 trials. Pfizer continues to expand its RSV vaccine ABRYSVO into younger adult age groups. These developments are expected to intensify competition, improve product innovation, and lower costs over time, which is crucial for sustaining long-term market growth, particularly in emerging economies.

Additionally, partnerships with global health organizations and tiered pricing strategies will be key in expanding RSV vaccine access across low- and middle-income countries. As climate change and global mobility contribute to changes in RSV seasonality and transmission patterns, integrated surveillance and responsive vaccination policies will be increasingly important. With expanding recommendations and a strong innovation pipeline, the RSV vaccine market is poised for continued growth and public health impact.

Respiratory Syncytial Virus Vaccines Market Report Highlights:

  • In 2024, passive immunization led the market with a market share of 75.02%, primarily driven by advancements in monoclonal antibody (mAb) therapies.
  • The monoclonal antibodies (mAbs) segment secured the dominant market share in 2024. mAbs offer immediate passive immunity, making them ideal for protecting high-risk populations such as newborns and immunocompromised individuals.
  • The infants and children held the largest market share of 75.02% in 2024, due to the high disease burden and recent preventive breakthroughs. RSV is the leading cause of hospitalization in infants globally, prompting urgent demand for effective protective measures.
  • Hospital & retail pharmacies are expected to dominate the market in 2024 with share of 53.68% fueled by rising demand, vaccine accessibility, and expanding immunization programs.
  • North America holds a substantial share of the global RSV vaccine market, attributed to the high prevalence of RSV infections and advanced healthcare infrastructure.
  • The global RSV vaccines market is highly competitive, with key players such as AstraZeneca, Sanofi, GSK, Pfizer, Moderna, Icosavax, Meissa Vaccines, Codagenix, Blue Lake Biotechnology, and Merck, focusing on enhancing the vaccine.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. RSV (Respiratory Syncytial Virus) Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. RSV (Respiratory Syncytial Virus) Vaccines Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. RSV (Respiratory Syncytial Virus) Vaccines Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Type Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Passive Immunization
    • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Preventive Vaccines
    • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. RSV (Respiratory Syncytial Virus) Vaccines Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Technology Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Monoclonal Antibodies
    • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Recombinant Protein + Adjuvant
    • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. mRNA-Based Vaccine
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Virus-Like Particle (VLP)
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. RSV (Respiratory Syncytial Virus) Vaccines Market: Targeted Population Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Targeted Population Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Adults
    • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Infants and children
    • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. RSV (Respiratory Syncytial Virus) Vaccines Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. RSV (Respiratory Syncytial Virus) Vaccines Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 7.3. Hospital & Retail Pharmacies
    • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Government Suppliers
    • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Others
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. RSV (Respiratory Syncytial Virus) Vaccines Market: Regional Estimates & Trend Analysis

  • 8.1. RSV (Respiratory Syncytial Virus) Vaccines Market Share, By Region, 2024 & 2030 (USD Million)
  • 8.2. North America
    • 8.2.1. North America RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Norway RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. China RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Australia RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. South Korea RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. South Africa RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. UAE RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait RSV (Respiratory Syncytial Virus) Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. AstraZeneca
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Sanofi
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. GSK
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Pfizer Inc.
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. Moderna
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Icosavax
      • 9.4.6.1. Financial Performance
      • 9.4.6.2. Product Benchmarking
      • 9.4.6.3. Recent Developments/ Strategic Initiatives
    • 9.4.7. Meissa Vaccines
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Codagenix
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Blue Lake Biotechnology
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Merck & Co., Inc.
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1. List of abbreviation
  • Table 2. Global RSV (Respiratory Syncytial Virus) vaccines market, by region, 2018 - 2030 (USD Million)
  • Table 3. Global RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 4. Global RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 5. Global RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 6. Global RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7. North America RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 9. North America RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 10. North America RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 11. North America RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 13. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 14. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 15. U.S. RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16. Canada RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 17. Canada RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 18. Canada RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 19. Canada RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 21. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 22. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 23. Mexico RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. Europe RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 25. Europe RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 26. Europe RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 27. Europe RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 28. Europe RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29. UK RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 30. UK RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 31. UK RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 32. UK RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Germany RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 34. Germany RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 35. Germany RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 36. Germany RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37. France RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 38. France RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 39. France RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 40. France RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41. Italy RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 42. Italy RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 43. Italy RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 44. Italy RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Spain RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 46. Spain RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 47. Spain RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 48. Spain RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 50. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 51. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 52. Denmark RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 54. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 55. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 56. Sweden RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57. Norway RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 58. Norway RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 59. Norway RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 60. Norway RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66. Japan RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 67. Japan RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 68. Japan RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 69. Japan RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70. China RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 71. China RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 72. China RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 73. China RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74. India RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 75. India RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 76. India RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 77. India RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78. Australia RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 79. Australia RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 80. Australia RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 81. Australia RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 83. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 84. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 85. South Korea RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 87. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 88. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 89. Thailand RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 91. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 92. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 93. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 94. Latin America RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 96. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 97. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 98. Brazil RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 100. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 101. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 102. Argentina RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103. MEA RSV (Respiratory Syncytial Virus) vaccines market, by country, 2018 - 2030 (USD Million)
  • Table 104. MEA RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 105. MEA RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 106. MEA RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 107. MEA RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 109. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 110. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 111. South Africa RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116. UAE RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 117. UAE RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 118. UAE RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 119. UAE RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 121. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by technology, 2018 - 2030 (USD Million)
  • Table 122. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by targeted population, 2018 - 2030 (USD Million)
  • Table 123. Kuwait RSV (Respiratory Syncytial Virus) vaccines market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 RSV (Respiratory Syncytial Virus) vaccines market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 RSV (Respiratory Syncytial Virus) vaccines market: Product outlook key takeaways
  • Fig. 20 RSV (Respiratory Syncytial Virus) vaccines market: Type movement analysis
  • Fig. 21 Passive immunization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Preventive vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 RSV (Respiratory Syncytial Virus) vaccines market: Technology outlook key takeaways
  • Fig. 24 RSV (Respiratory Syncytial Virus) vaccines market: Technology movement analysis
  • Fig. 25 Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Recombinant Protein + Adjuvant market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 mRNA-based vaccine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 RSV (Respiratory Syncytial Virus) vaccines market: Targeted Population outlook key takeaways
  • Fig. 29 RSV (Respiratory Syncytial Virus) vaccines market: Targeted Population movement analysis
  • Fig. 30 Adults market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Infants and children market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 RSV (Respiratory Syncytial Virus) vaccines market: Distribution Channel outlook key takeaways
  • Fig. 33 RSV (Respiratory Syncytial Virus) vaccines market: Distribution Channel movement analysis
  • Fig. 34 Hospital & retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Government suppliers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Regional marketplace outlook, 2024 & 2030 (USD million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 North America RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 US RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Canada RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Mexico RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Europe RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Germany RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Spain RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Norway RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 China RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 India RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Australia RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 South Korea RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Thailand RSV (Respiratory Syncytial Virus) vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Market participant categorization
  • Fig. 78 RSV (Respiratory Syncytial Virus) vaccines market position analysis, 2024
  • Fig. 79 Strategic framework